Pharma Mirror

FEBRUARY 18, 2021

A novel approach for ensuring the virtually unlimited production of QS-21, the ‘Gold Standard’ adjuvant for improving vaccine efficacy, will be the subject of an upcoming presentation at the BIO CEO & Investor Digital Conference, starting February 16.

Immunization 52

Immunization Vaccines 52

pharmaphorum

JULY 26, 2022

For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. The concept of pre-emptively training the immune system to increase the frequencies of tumour-reactive T cells could be game-changing for cancer patients worldwide. And for good reason.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

JANUARY 21, 2021

While restrictions on travel could prevent coronavirus transmission in the short term, digital passports showing COVID-negative and vaccination status may help reopen airports and other badly hit areas of the economy, reports Richard Staines. But could digital immunity passports be the answer?

Vaccines 85

Vaccines Immunization Hospitals 85

Pharma Mirror

OCTOBER 16, 2023

The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021. The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.

Immunization 52

Immunization Vaccines FDA 52

pharmaphorum

DECEMBER 23, 2022

In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. The post After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer appeared first on.

Immunization 52

Immunization Hospitals Vaccines 52

PharmaShots

MARCH 9, 2023

Birthplace: Belén was born in Almansa (Spain) Additional Information: Merck became a significant international participant in immunology, oncology, and immune oncology under her leadership of the Healthcare business. Designation: Global Head Previous company: Merck Global Vaccines (2 yrs. and Banco Bilbao Vizcaya Argentaria S.A

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

ISPE

OCTOBER 27, 2022

This can be challenging for many reasons: it can be difficult to estimate the size and number of polynucleotides to transfer, the efficiency of the vector in the particular cells addressed, the scale of production required, and whether a patient’s immune system will respond to vector particles as a microorganism. Accessed 11 August 2022.

Packaging 52

Packaging Communication Immunization Vaccines 52